BioSenic S.A. (LON:0R55)

Market Cap	1.36M +15.3%
Revenue (ttm)	-2.05M -69.6%
Net Income	-3.43M
EPS	-0.01
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	26,480
Average Volume	186,553
Open	0.0024
Previous Close	0.0023
Day's Range	0.0023 - 0.0024
52-Week Range	0.0010 - 0.0060
Beta	-2.29
RSI	47.16
Earnings Date	Apr 24, 2026

About BioSenic

BioSenic S.A., a biotechnology company, develops cell therapy products and treatments for autoimmune and inflammatory diseases in Belgium and France. The company offers arsenic trioxide (ATO) and oral arsenic trioxide (OATO) platforms. It also provides medicinal products, including ArsciMed, an intravenous drug to treat autoimmune diseases. In addition, the company develops 4P004v which is in Phase I clinical trial for veterinary use. BioSenic S.A. is headquartered in Saintes, Belgium.

• Industry: Biotechnology
• Sector: Healthcare
• CEO: Jean-Luc Vandebroek
• Employees: 7
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0R55

Financial Performance

In 2024, BioSenic's revenue was 102,000, a decrease of -69.64% compared to the previous year's 336,000. Losses were -4.77 million, -83.43% less than in 2023.

Financial numbers in EUR